Harvard’s Wyss Institute is partnering with Cellectis, a company working on immunotherapy technology involving editing the genes of allogeneic CAR T-cells, to create “virus-resistant human cells.” These would be used to produce therapeutic products and to create new cell-based clinical therapies.